Robert Alter

4.1k total citations
29 papers, 466 citations indexed

About

Robert Alter is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Robert Alter has authored 29 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Robert Alter's work include Renal cell carcinoma treatment (18 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Renal and related cancers (8 papers). Robert Alter is often cited by papers focused on Renal cell carcinoma treatment (18 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Renal and related cancers (8 papers). Robert Alter collaborates with scholars based in United States, United Kingdom and Spain. Robert Alter's co-authors include Stanley E. Waintraub, Stuart L. Goldberg, Andrew L. Pecora, Scott D. Rowley, Robert A. Preti, Michael B. Atkins, David F. McDermott, Elizabeth R. Plimack, Peter J. Van Veldhuizen and Jennifer L. Johansen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Robert Alter

29 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Alter United States	10	264	206	132	91	88	29	466
Smitha Menon United States	11	300 1.1×	128 0.6×	134 1.0×	75 0.8×	73 0.8×	18	474
Carla M. van Herpen Netherlands	14	325 1.2×	146 0.7×	195 1.5×	113 1.2×	52 0.6×	27	608
Katrin Bankov Germany	14	189 0.7×	126 0.6×	129 1.0×	66 0.7×	73 0.8×	36	481
Sara Elena Rebuzzi Italy	15	394 1.5×	331 1.6×	117 0.9×	54 0.6×	107 1.2×	67	643
Angélique Brunot France	12	117 0.4×	134 0.7×	112 0.8×	52 0.6×	67 0.8×	29	346
J. Luz Tovar García Colombia	7	275 1.0×	140 0.7×	145 1.1×	276 3.0×	68 0.8×	8	591
Naomi Guppy United Kingdom	14	182 0.7×	88 0.4×	188 1.4×	70 0.8×	94 1.1×	21	473
Donald Woytowitz United States	11	477 1.8×	397 1.9×	172 1.3×	146 1.6×	64 0.7×	19	731
Opeyemi A. Jegede United States	12	329 1.2×	341 1.7×	183 1.4×	96 1.1×	153 1.7×	59	619
Zaida Morante Peru	11	266 1.0×	140 0.7×	149 1.1×	113 1.2×	142 1.6×	38	479

Countries citing papers authored by Robert Alter

Since Specialization

Citations

This map shows the geographic impact of Robert Alter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Alter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Alter more than expected).

Fields of papers citing papers by Robert Alter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Alter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Alter. The network helps show where Robert Alter may publish in the future.

Co-authorship network of co-authors of Robert Alter

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Alter. A scholar is included among the top collaborators of Robert Alter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Alter. Robert Alter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer. 12(4). e008293–e008293. 2 indexed citations

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

Calvo, Mariona, Konstantin Penkov, Alexander I. Spira, et al.. (2023). A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). TPS282–TPS282. 3 indexed citations

Atkins, Michael B., Opeyemi A. Jegede, David F. McDermott, et al.. (2023). Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).. Journal of Clinical Oncology. 41(6_suppl). 604–604. 4 indexed citations

Choueiri, Toni K., Michael B. Atkins, Tracy L. Rose, et al.. (2021). A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs. 39(4). 1019–1027. 34 indexed citations

Tykodi, Scott S., Lucio Gordan, Robert Alter, et al.. (2021). Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.. Journal of Clinical Oncology. 39(6_suppl). 309–309. 13 indexed citations

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2021). Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).. Journal of Clinical Oncology. 39(15_suppl). 4510–4510. 4 indexed citations

Zhang, Jingsong, David D. Chism, Scott T. Tagawa, et al.. (2019). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 197–197. 1 indexed citations

Voss, Martin H., Rupal S. Bhatt, Nicholas J. Vogelzang, et al.. (2019). A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 125(14). 2400–2408. 21 indexed citations

10.

Galsky, Matt D., Sumanta K. Pal, Amir Mortazavi, et al.. (2019). Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. Journal of Clinical Oncology. 37(15_suppl). 4504–4504. 17 indexed citations

11.

Choueiri, Toni K., M.B. Atkins, Tracy L. Rose, et al.. (2018). A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy. Annals of Oncology. 29. viii402–viii403. 5 indexed citations

12.

Atkins, Michael B., Richard W. Joseph, Thai H. Ho, et al.. (2018). Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC). Molecular Cancer Therapeutics. 17(1_Supplement). B201–B201. 5 indexed citations

13.

McDermott, David F., Richard W. Joseph, Thai H. Ho, et al.. (2017). A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC). Annals of Oncology. 28. v317–v318. 1 indexed citations

14.

Choueiri, Toni K., Camillo Porta, C. Suárez Rodríguez, et al.. (2017). A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy. Annals of Oncology. 28. v328–v328. 2 indexed citations

15.

Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565. 21 indexed citations

16.

Sanchez, Larysa, Yucai Wang, Narjust Duma, et al.. (2016). Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: A meta-analysis.. Journal of Clinical Oncology. 34(15_suppl). e16505–e16505. 1 indexed citations

17.

Voss, Martin H., Elizabeth R. Plimack, Brian I. Rini, et al.. (2015). DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.. Journal of Clinical Oncology. 33(7_suppl). 407–407. 2 indexed citations

18.

Atkins, Michael B., Rupal S. Bhatt, Martin H. Voss, et al.. (2013). Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4595–TPS4595. 1 indexed citations

19.

Goldberg, Stuart L., Andrew L. Pecora, Robert Alter, et al.. (2002). Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 99(4). 1486–1488. 133 indexed citations

20.

Chachoua, Abraham, Ruth Oratz, Leonard Liebes, et al.. (1994). Phase Ib Trial of Granulocyte-Macrophage Colony-Stimulating Factor Combined with Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma. Journal of Immunotherapy. 16(2). 132–141. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact